U.S. Markets closed

VioQuest Pharmaceuticals Inc. (VOQP)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0080.00 (0.00%)
At close: 12:10PM EDT
People also watch

VioQuest Pharmaceuticals Inc.

180 Mount Airy Road
Suite 102
Basking Ridge, NJ 07920
United States

Full Time Employees3

Key Executives

Dr. Yaping Hong Ph.D.Sr. VP of Global Process R&DN/AN/A61
Mr. Mark D. DackoController and Assistant Sec.N/AN/A66
Dr. Michael Cannarsa Ph.D.Gen. Mang. of Chiral QuestN/AN/A60
Dr. Lawrence Akinsanmi M.D., Ph.D.VP of Clinical Operations & Regulatory AffairsN/AN/AN/A
Dr. Vernon L. Alvarez Ph.D.VP of R&DN/AN/AN/A
Amounts are as of December 31, 2006 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


VioQuest Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of clinical stage drug therapies for the treatment of oncology and infectious diseases. Its lead product includes Xyfid, which is under development for the treatment and prevention of hand-foot syndrome. The company’s products also consist of VQD-002, a nucleoside analog that is in Phase I clinical trials for the treatment of cancer; and Lenocta, a small molecule inhibitor of various protein tyrosine phosphatases, which is in Phase IIa clinical trials for the treatment of melanoma, renal cell carcinoma, and other solid tumors. VioQuest Pharmaceuticals also provides chiral products, technology, and custom synthesis development services to pharmaceutical and fine chemical companies in various stages of a products’ lifecycle. The company was founded in 2000 and is headquartered in Basking Ridge, New Jersey.

Corporate Governance

VioQuest Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.